HR 2374
116th Congress
House
Health
Administrative law and regulatory procedures
Business ethics
Civil actions and liability
Competition and antitrust
Drug safety, medical device, and laboratory regulation
Federal Trade Commission (FTC)
Licensing and registrations
Public participation and lobbying
Stop STALLING Act
Introduced: April 29, 2019
Introduced by:
Jeffries, Hakeem S.
Democratic
· New York
See on congress.gov
Everywhere this bill has been
6 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Dec 24, 2020
Placed on the Union Calendar, Calendar No. 577.
Dec 24, 2020
Reported by the Committee on Judiciary. H. Rept. 116-694.
Apr 30, 2019
Ordered to be Reported by Voice Vote.
Apr 30, 2019
Committee Consideration and Mark-up Session Held.
Apr 29, 2019
Referred to the House Committee on the Judiciary.
Apr 29, 2019
Introduced in House
Plain-English summary
Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act
This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit shall be subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.
What's happening now
Placed on the Union Calendar, Calendar No. 577.
Committees of jurisdiction
1